Protalix investing

Author: azri

August undefined, 2024

WebbThis page contains information on users’ sentiments for the Protalix Biotherapeutics Inc stock, which are displayed both on charts of different periods of time and on a detailed … Webb11 apr. 2024 · Protalix BioTherapeutics (NYSE:PLX) has a market capitalization of $126.75 million and generates $47.64 million in revenue each year. The company earns $-14,930,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis.

Forum su Protalix (PLX) - Investing.com

WebbProtalix Biotherapeutics Inc Börsvärde är idag 82,585 M. Jämför den aktuella Börsvärde med historisk prestanda och jämför PLX Börsvärde med konkurrenter. HARP -21.2% IBIO … WebbPLX Smart Score - Investing.com Protalix Biotherapeutics Inc (PLX) NYSE Create Alert Add to Watchlist 2.240 +0.030 +1.36% 09:48:35 - Real-time Cboe. Currency in USD ( Disclaimer ) Type: Equity... they\u0027ve 95

Protalix BioTherapeutics Issues 2024 Letter to Stockholders

Webb4 juli 2024 · Source: Company Annual Report & estimates, PLX Investor Presentation. The CRL Hiccup. Protalix and Chiesi had submitted the BLA for PRX-102 post its successful completion of Phase 1/2 with the FDA ... Webb21 dec. 2024 · Protalix BioTherapeutics, Inc. Dec 21, 2024, 16:30 ET. The Company's Common Stock will continue to trade on the NYSE American. CARMIEL, Israel, Dec. 21, 2024 /PRNewswire/ -- Protalix ... WebbProtalix is dedicated to bringing to market recombinant therapeutic proteins with clinically improved profiles, produced with our ProCellEx ® plant cell-based expression system … safranin in hindi

Protalix Biotherapeutics Inc (PLX) Kassaflöde - Investing.com

WebbFå detaljerad information om utdelningsdatum och utdelningsmeddelanden för Protalix. WebbProtalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease . Corporate history [ edit] Protalix BioTherapeutics was established in 1993. [3] they\\u0027ve 93Webb27 feb. 2024 · Investing.com - Protalix (NYSE: PLX) reported fourth quarter EPS of $-0.220, $0.07 worse than the analyst estimate of $-0.150. Revenue for the quarter came in at $62.89M versus the consensus... they\\u0027ve 95

"WebbProtalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. " - Protalix investing

Protalix investing

WebbDenna sida innehåller balansräkningen för Protalix Biotherapeutics Inc, som sammanfattar bolagets finansiella ställning, inklusive tillgångar, skulder och mycket mer. Heta nyheter …

Did you know?

WebbDen här sidan ger en fördjupad profil av Protalix Biotherapeutics Inc, inklusive en allmän översikt av företagets affärsverksamhet och ansvarig ledning. Webb10 feb. 2024 · Investing Groups Leader Follow Summary Shares of plant-derived enzyme therapy concern Protalix BioTherapeutics, Inc. have rallied after its Fabry disease asset PLX-102 received a PDUFA date of...

Webb6 jan. 2024 · By Investing.com - Feb 27, 2024 Protalix BioTherapeutics (PLX) reported Q4 EPS of ($0.22), $0.07 worse than the analyst estimate of ($0.15). Revenue for the quarter … Webb21 mars 2024 · This table contains core financial ratios such as Price-to-Earnings , Return-On-Investment (ROI), Earnings per share (EPS), Dividend yield and others based on Protalix Biotherapeutics Inc's latest ...

WebbProtalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. Webb5 dec. 2024 · About Protalix; Elelyso ® Management; Board of Directors; Scientific Advisory Board; Environmental Monitoring; Careers; Technology. ProCellEx ® Platform; Orally …

Webb31 mars 2024 · Of the 23 institutional investors that purchased Protalix BioTherapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Psagot Investment House Ltd. ($2.63M), Morgan Stanley ($1.86M), DAFNA Capital Management LLC ($1.20M), Meitav Dash Investments Ltd. …

WebbErhåll gratis data i optionskedjan för PLX. Hitta köp- och säljoptioners kurser, slutkurs, förändring, volym, och mer för Protalix Aktieoptioner. they\\u0027ve 9bWebbPLX Smart Score - Investing.com Protalix Biotherapeutics Inc (PLX) NYSE Create Alert Add to Watchlist 2.240 +0.030 +1.36% 09:48:35 - Real-time Cboe. Currency in USD ( … safranin functionWebb13 apr. 2024 · With the market capitalization of Protalix BioTherapeutics Inc. currently standing at about $135.59 million, investors are eagerly awaiting this quarter’s results, scheduled for May 15, 2024 – May 19, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. they\u0027ve 94WebbFå omedelbar tillgång till ett gratis live streamade Protalix Biotherapeutics Inc diagram. they\u0027ve 96Webb12 apr. 2024 · By Hasnain Raza. April 12, 2024. Protalix BioTherapeutics Inc. (PLX) currently has a stock price of $2.50. The stock saw a sharp increase in the last trading session, hitting a high of $2.35 after opening at $2.30. The lowest recorded price for the day was $2.27 before it closed at $2.35. safranin o and fast greenWebbAlla relevanta kommentarer och diskussioner sammanställda om PLX Aktien. they\\u0027ve 97Webb28 mars 2024 · The average price point forecasted by analysts for Protalix BioTherapeutics Inc. (PLX) is $11.00, The public float for PLX is 48.36M, and currently, short sellers hold a 10.65% ratio of that floaft. The average trading volume of PLX on March 28, 2024 was 993.42K shares. PLX) stock’s latest price update they\\u0027ve 98